BioSpace News Archive

In a strategic reorganization announced Thursday, Axcella Therapeutics will focus its resources on its Long COVID program and slash headcount by 85%.

Third Harmonic Bio drops its Phase 1b asset.

BioCryst Pharmaceuticals is discontinuing the development of its Factor D inhibitor BCX9930 in paroxysmal nocturnal hemoglobinuria due to competitive factors.

AbbVie and AbCellera inked an antibody discovery deal to develop candidates for up to five targets in several indications.

Providence Therapeutics Holdings Inc. (“Providence”), a clinical-stage biotechnology company pioneering mRNA vaccines for infectious diseases and oncology, today announced that its new mRNA vaccine program for rabies post-exposure prophylaxis has achieved a preclinical proof-of-concept milestone.

PDS Biotechnology Corporation (Nasdaq: PDSB) today announced the completion of enrollment in the first stage of the checkpoint inhibitor refractory group of its VERSATILE-002 Phase 2 study for the potential treatment of recurrent and/or metastatic human papillomavirus (HPV16)-positive head and neck cancer.

PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty ketamine pharmaceuticals, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for ketamine in the prevention of ischemia-reperfusion injury from organ transplantation.

aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced new findings from its tRNA synthetase platform.

Ehave, Inc. announced today that it received confirmation from the U.S. Food and Drug Administration (“FDA”) that its review of Ehave’s Investigational New Drug (“IND”) application is complete.

Duality Biotherapeutics, Inc. announced the appointment of Dr. Pasi A. Jänne as member of SAB.